Indianapolis court backs patent for Lilly cancer drug Alimta
A federal court has upheld the patent that protects Eli Lilly and Co.'s lung-cancer treatment from generic competition until 2022.
A federal court has upheld the patent that protects Eli Lilly and Co.'s lung-cancer treatment from generic competition until 2022.
A number of Indiana lawmakers – including both of the state’s U.S. senators – have advocated for the elimination of the tax, in part because the state is home to several key medical device manufacturers.
The 7 million target, thought to be out of reach by most experts, was in sight on a day that saw surging consumer interest as well as vexing computer glitches.
The last-minute flood of applicants in Indiana mirrored national trends as people sought to at least start the process Monday.
Indiana University Health’s business deteriorated last year in nearly every area. But price hikes and a surge in outpatient visits to Indianapolis-area facilities mostly offset those problems.
Now that Indiana-based Endocyte Inc.’s experimental cancer treatment is proving successful, the company may command a takeover bid at one of the industry’s highest premiums on record.
Afrezza, a powdered insulin used through an inhaler, would be the MannKind Corp.’s first marketed product. The treatment would compete against Lilly’s Humalog. An FDA report tied the drug to a decline in lung function.
Like much else about Obama's health care law, the milestone comes with a caveat: The administration has yet to announce how many consumers actually closed the deal by paying their first month's premium.
People who've started applying for health insurance but aren't able to finish before the March 31 enrollment deadline will get extra time, the Obama administration announced Tuesday.
The health insurer predicted growth in government-funded health insurance programs would push revenue above $100 billion by 2018. That prompted investors to push WellPoint stock above $100 per share—an all-time high for the company.
Lilly CEO John Lechleiter was paid $11.2 million in salary, bonus, stock and perks last year, according to Lilly’s proxy statement filed Monday morning. That represented a 10-percent increase over his take in 2012.
The stock price of Endocyte Inc. skyrocketed by as much as 130 percent Friday morning after the drug company got a thumbs up in Europe to market its first drug and received a new round of favorable clinical trial results.
Indianapolis-based Lilly is expected to garner $518 million in annual sales from Jardiance by 2019, according to the average of five analyst estimates compiled by Bloomberg.
Zeke Turner, the 36-year-old CEO of Mainstreet Property Group LLC—who frequently sports a boyish grin and a bold-colored dress shirt, but rarely dons a tie—said he’s “just getting started” in transforming the staid nursing home industry.
Scientists have discovered that a gene-regulating protein that protects the developing brain of a fetus resurfaces in old age and may stave off dementia, a finding that could open a new path in Alzheimer’s research.
A snapshot of Obamacare enrollment in seven states suggests the law hasn’t significantly increased competition, but it has shuffled market share for some insurers, including Indianapolis-based WellPoint Inc.
Anthem Blue Cross and Blue Shield has signed a new kind of contract with the Franciscan Alliance hospital system that allows Franciscan to make more money only if it saves money for Anthem.
Obamacare opponents predicted early on that insurance co-ops created by the law would fail, but several are doing well by combining low premiums with a certain homespun appeal.
Nearly 65,000 Indiana residents have signed up for private insurance under the federal health care law, but the number is still far short of initial projections as the open enrollment deadline nears.
House Public Health Chairman Ed Clere said Tuesday that negotiators had found a compromise that would ban new construction for two years except in counties whose nursing homes are at 90-percent capacity or higher.